{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:45:43Z","timestamp":1790019943899,"version":"4.0.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Acute myeloid leukemia (AML) is characterized by the accumulation of cytogenetic and molecular abnormalities. Isocitrate dehydrogenase 1 and 2 (<jats:italic toggle=\"yes\">IDH1\/2<\/jats:italic>) mutations occur in 11% to 20% of adults with AML. The outcome of <jats:italic toggle=\"yes\">IDH1\/2<\/jats:italic>-mutated AML is heterogeneous and affected by co-mutational patterns. We retrospectively analyzed 118 patients with <jats:italic toggle=\"yes\">IDH1\/2<\/jats:italic>-mutated AML who were retrieved from 1597 patients newly diagnosed with AML and treated with intensive chemotherapy. Univariate analysis revealed the <jats:italic toggle=\"yes\">NPM1<\/jats:italic> mutation was a favorable factor (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.019) for overall survival (OS), whereas the <jats:italic toggle=\"yes\">DNMT3A<\/jats:italic> mutation was consistently associated with a poor outcome (3-year OS, 52.0%; 3-year relapse-free survival [RFS], 44.8%; and 3-year cumulative incidence of relapse [CIR], 42.6%). Interestingly, the <jats:italic toggle=\"yes\">DNMT3A<\/jats:italic> mutation still identified patients with a poorer prognosis, even when measurable residual disease (MRD) was negative after 2 courses of chemotherapy. In a multivariate regression model, age, <jats:italic toggle=\"yes\">DNMT3A<\/jats:italic> mutation and MRD positivity were retained as independent adverse markers for OS, RFS, and CIR. In the absence of the <jats:italic toggle=\"yes\">DNMT3A<\/jats:italic> or <jats:italic toggle=\"yes\">FLT3<\/jats:italic>-ITD mutations, the <jats:italic toggle=\"yes\">NPM1<\/jats:italic> mutation identified patients with a very favorable OS (3-year OS, 96.3% and 86.3%, respectively). Finally, hematopoietic stem cell transplantation in first complete remission significantly improved RFS (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.015) and there was a trend toward improvement in OS (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.282) for patients with the <jats:italic toggle=\"yes\">DNMT3A<\/jats:italic> mutation but it did not benefit 2 subgroups with the <jats:italic toggle=\"yes\">IDH1\/2<\/jats:italic>+\/<jats:italic toggle=\"yes\">NPM1<\/jats:italic>+\/<jats:italic toggle=\"yes\">DNMT3A<\/jats:italic>\u2212 and <jats:italic toggle=\"yes\">IDH1\/2<\/jats:italic>+\/<jats:italic toggle=\"yes\">NPM1<\/jats:italic>+\/<jats:italic toggle=\"yes\">FLT3<\/jats:italic>-ITD\u2212 genotypes. In summary, this study provides a reference for risk stratification and treatment implications for patients with <jats:italic toggle=\"yes\">IDH1\/2<\/jats:italic>-mutated AML as well as for comparison with results of IDH inhibitor- or venetoclax-based combination therapy.<\/jats:p>","DOI":"10.1097\/bs9.0000000000000231","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T20:03:34Z","timestamp":1743365014000},"page":"e00231","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic impact of co-mutations in adults with IDH1\/2-mutated acute myeloid leukemia"],"prefix":"10.1097","volume":"7","author":[{"given":"Anli","family":"Lai","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbing","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Zhou","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuning","family":"Wei","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqi","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benfa","family":"Gong","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Gong","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxia","family":"Gu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Qiu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wei","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, Tianjin 301600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"23","key":"R1-20250328","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia.","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"R2-20250328","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"issue":"19","key":"R3-20250328","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of IDH mutations in AML","volume":"7","author":"Zarnegar-Lumley","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"R4-20250328","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov"},{"issue":"7390","key":"R5-20250328","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation.","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"6","key":"R6-20250328","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"25","key":"R7-20250328","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML.","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"R8-20250328","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"1","key":"R9-20250328","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia.","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"R10-20250328","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"issue":"20","key":"R11-20250328","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1182\/blood-2011-03-343988","article-title":"Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.","volume":"118","author":"Shen","year":"2011","journal-title":"Blood"},{"issue":"8","key":"R12-20250328","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"issue":"5","key":"R13-20250328","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","article-title":"Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.","volume":"6","author":"Middeke","year":"2022","journal-title":"Blood Adv"},{"issue":"22","key":"R14-20250328","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"20","key":"R15-20250328","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.2020010165","article-title":"Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.","volume":"137","author":"Duchmann","year":"2021","journal-title":"Blood"},{"issue":"9","key":"R16-20250328","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/leu.2014.124","article-title":"DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.","volume":"28","author":"Im","year":"2014","journal-title":"Leukemia"},{"key":"R17-20250328","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2147\/CMAR.S157632","article-title":"Clinical and biological implications of IDH1\/2 in acute myeloid leukemia with DNMT3A(mut).","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"8","key":"R18-20250328","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/ajh.25517","article-title":"The combination of NPM1, DNMT3A, and IDH1\/2 mutations leads to inferior overall survival in AML.","volume":"94","author":"Dunlap","year":"2019","journal-title":"Am J Hematol"},{"issue":"32","key":"R19-20250328","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"R20-20250328","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia.","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"R21-20250328","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"1","key":"R22-20250328","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26757","article-title":"Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.","volume":"98","author":"Stahl","year":"2023","journal-title":"Am J Hematol"},{"issue":"29","key":"R23-20250328","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1200\/JCO.22.02868","article-title":"What influences the decision to proceed to transplant for patients with AML in first remission?","volume":"41","author":"DeWolf","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"R24-20250328","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"5","key":"R25-20250328","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML.","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"R26-20250328","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/bloodadvances.2021005789","article-title":"Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.","volume":"7","author":"Bill","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"R27-20250328","doi-asserted-by":"crossref","first-page":"e35641","DOI":"10.1002\/cncr.35641","article-title":"Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia.","volume":"131","author":"Zhang","year":"2024","journal-title":"Cancer"},{"issue":"8","key":"R28-20250328","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2012.0103","article-title":"NCCN Clinical Practice Guidelines Acute myeloid leukemia.","volume":"10","author":"O\u2019Donnell","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"R29-20250328","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-024-01144-1","article-title":"Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia.","volume":"14","author":"Liu","year":"2024","journal-title":"Blood Cancer J"},{"issue":"345","key":"R30-20250328","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/01621459.1974.10480131","article-title":"Evaluation of response-time data involving transient states: an illustration using heart-transplant data.","volume":"69","author":"Mantel","year":"1974","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"R31-20250328","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics.","volume":"48","author":"Kanda","year":"2013","journal-title":"J Bone Marrow Transplant"},{"key":"R32-20250328","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate\u2014a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Stat Soc Ser B"},{"issue":"3","key":"R33-20250328","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"12","key":"R34-20250328","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"R35-20250328","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-5-5","article-title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.","volume":"5","author":"Chotirat","year":"2012","journal-title":"J Hematol Oncol"},{"issue":"7834","key":"R36-20250328","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies.","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"3","key":"R37-20250328","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41375-020-0932-8","article-title":"Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.","volume":"35","author":"Cerrano","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"R38-20250328","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood.2019003330","article-title":"Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.","volume":"135","author":"Zhang","year":"2020","journal-title":"Blood"},{"issue":"23","key":"R39-20250328","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1182\/bloodadvances.2024013758","article-title":"Measurable residual disease monitoring in AML With FLT3-ITD treated with intensive chemotherapy plus midostaurin.","volume":"8","author":"R\u00fccker","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"R40-20250328","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbmt.2015.07.030","article-title":"DNMT3A R882 mutation with FLT3-ITD positivity is an extremely poor prognostic factor in patients with normal-karyotype acute myeloid leukemia after allogeneic hematopoietic cell transplantation.","volume":"22","author":"Ahn","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"R41-20250328","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ng.3756","article-title":"Precision oncology for acute myeloid leukemia using a knowledge bank approach.","volume":"49","author":"Gerstung","year":"2017","journal-title":"Nat Genet"},{"issue":"11","key":"R42-20250328","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/ajh.26694","article-title":"Contemporary outcomes in IDH-mutated acute myeloid leukemia: the impact of co-occurring NPM1 mutations and venetoclax-based treatment.","volume":"97","author":"Lachowiez","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Blood Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T20:09:52Z","timestamp":1743365392000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bs9.0000000000000231","relation":{},"ISSN":["2543-6368"],"issn-type":[{"value":"2543-6368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}